Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

F.D.A. Advisers Endorse Paxlovid’s Benefits as a Covid Treatment

The New York Times – Business:

While an agency analysis did find signs of Covid “rebound,” the drug significantly reduces hospitalizations and deaths, researchers said.

Carl Zimmer
Author: Carl Zimmer

This post first appeared in The New York Times – Business. Read the original article.

Written by

Carl Zimmer

in

Coronavirus (2019-nCoV), Drugs (Pharmaceuticals), Food and Drug Administration, Paxlovid (Drug), Pfizer Inc, United States
←Tauba Auerbach’s Work Might (Possibly) Have Its Own Free Will
For Jean-Yves Thibaudet, a Detour From Classical Is Business as Usual→

More posts

  • US, China agree to cut tariffs on $30 billion worth of goods, set up channel for AI incidents

  • The future is here: What will a Millennial-Gen Z majority mean for America? 

  • OPINION: Trump’s U.N. speech, a stark contrast with past presidents

  • Why Democrats stopped talking about climate

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube